Biogen Inc. Common Stock
BIIBBiogen Inc. is a biotechnology company specializing in the development and commercialization of therapies for neurological and neurodegenerative diseases. Founded in 1978, it is known for its work in multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. Biogen focuses on innovative biologic medicines and research-driven solutions to address complex neurological conditions.
Company News
Eisai and Biogen announced that China's NMPA has accepted their Biologics License Application for a subcutaneous autoinjector formulation of LEQEMBI (lecanemab), an anti-amyloid beta antibody for early Alzheimer's disease treatment. If approved, this would be the first anti-amyloid treatment in China offering at-home injection from treatment init...
Royalty Pharma acquired the final portion of PTC Therapeutics' royalty on Roche's Evrysdi for $240 million upfront plus up to $60 million in milestones, giving it 100% ownership of the 8-16% tiered royalty. Evrysdi generated $1.9 billion in 2024 sales with projected growth to $2.9 billion by 2030. RPRX stock is up 53% year-to-date but down slight...
Novo Nordisk experienced a 10% stock drop after its semaglutide drug failed in Alzheimer's disease pivotal studies. Despite the setback, analysts suggest the company remains promising due to strong weight management and diabetes drug pipelines.
Pharmaceutical stocks rallied after Pfizer reached an agreement with the Trump administration to sell drugs at significant discounts, avoiding potential 100% tariffs. Multiple pharma companies saw substantial stock price increases.
Biogen reported strong Q2 results, beating earnings and revenue estimates. The company raised its 2024 guidance, driven by growth in new products like Leqembi and Skyclarys, offsetting declines in key multiple sclerosis drugs. However, the termination of a program with Denali Therapeutics weighed on the stock.
